作者
Nazli Dizman, Khyatiben Pathak, Marice Alcantara, Luis A Meza, Paulo Gustavo Bergerot, Maya Willey, Tanya B Dorff, Joann Hsu, Zeynep Busra Zengin, Daniela V Castro, Hedyeh Ebrahimi, Alex Chehrazi-Raffle, Abhishek Tripathi, Jeffrey M Trent, Motomichi Takahashi, Kentaro Oka, Seiya Higashi, Marcin Kortylewski, Patrick Pirrotte, Sumanta Kumar Pal
发表日期
2023/6/1
来源
Journal of Clinical Oncology
卷号
41
期号
16_suppl
页码范围
4556-4556
出版商
American Society of Clinical Oncology
简介
4556
Background: Recent evidence suggests that blood and stool SCFA levels (including acetic acid and butyric acid) are associated with clinical outcomes with immune checkpoint blockade in melanoma (Nomura et al. JAMA Network Open 2020). Herein, we report trends in plasma SCFA and cytokine levels in a randomized phase I clinical trial of CBM588, a live bacterial product containing a butyric acid-producing bacterium, C. butyricum, in patients with mRCC treated with immune checkpoint blockade. Methods: Treatment naïve patients with clear cell and/or sarcomatoid mRCC and intermediate- or high-risk IMDC disease were randomized to nivolumab/ipilimumab or nivolumab/ipilimumab and CBM588 in a 1:2 fashion. Blood samples were collected at baseline and on treatment (week 12 +/- 5 weeks). Quantitative assessment of plasma SCFAs and cytokines was performed by liquid chromatography-mass …
学术搜索中的文章
N Dizman, K Pathak, M Alcantara, LA Meza… - 2023